Tirzepatide Forschungspeptid – 99%+ Rein

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same source, same purity specification — scaled to whatever your research needs.

GLP1-RC-TZ Certificate of Analysis

GLP1-RC-TZ material is analysed by an independent laboratory, and the resulting Certificate of Analysis is published online. A certificate reports what was measured in the sample submitted; vials are not batch-marked, so it is not matched to a particular vial or order.

New-U GLP1-RC-TZ certificate evidence

Catalogue identifier: GLP1-RC-TZ

Independent testing laboratory, report number and test date

Measured purity for the sample analysed

Certificate of Analysis at /coa/tirzepatide; the method and any identity result are stated on the report

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Veröffentlichte Forschungsbereiche

Veröffentlichte Studien untersuchen receptor activity, Pharmakokinetik und protokolldefinierte metabolische, glykämische und insulin-sensitivity-Endpunkte. Die Zusammenfassungen unten berichten, was Forschende in diesen externen Studien gemessen haben, und sind keine Anwendungsanweisungen für das hier bereitgestellte Forschungsmaterial.

Rezeptor-Pharmakologie

Volle GIPR-Potenz neben cAMP-verzerrter GLP-1R-Signalgebung, charakterisiert in veröffentlichten in-vitro-Studien.

Metabolische Endpunkte

Protokolldefinierte Veränderung der Körpermasse gegenüber dem Ausgangswert, gemessen im SURMOUNT-Programm.

Glykämische Endpunkte

HbA1c als protokolldefinierter Endpunkt im SURPASS-Programm

Endpunkte der Insulin-Sensitivität

Marker der insulin sensitivity und adiponectin, gemessen zusammen mit direkter GIPR-vermittelter adipose signalling.

Pharmakokinetik

Systemische Exposition, Bioverfügbarkeit und scheinbare Halbwertszeit aus veröffentlichter pharmakokinetischer Charakterisierung.

Scientific Overview

In short: GLP1-RC-TZ ist ein dual GIPR / GLP-1R agonist research compound, das in Forschungsgemeinschaften häufig als „Tirz“ bezeichnet wird.

Key research facts

Rezeptor-Pharmakologie: duale GIPR / GLP-1R agonistische Aktivität in veröffentlichten in-vitro-Studien charakterisiert

Berichteter unausgeglichener Agonismus — volle GIPR-Potenz mit GLP-1R-Signalisierung, die cAMP gegenüber β-arrestin recruitment bevorzugt

Aib2- und Aib13-Substitutionen werden hinsichtlich DPP-IV- und Proteaseresistenz untersucht

Für die C20 fatty-diacid-Modifikation werden 99% Albuminbindung berichtet; die scheinbare Eliminationshalbwertszeit wird mit ~5 Tagen angegeben

SURMOUNT-1 RCT (NEJM 2022, PMID 35658024), 15 mg-Arm: Die Forschenden berichteten −20.9% mittlere Veränderung des Körpergewichts gegenüber dem Ausgangswert in Woche 72

These points summarise lab themes, not human outcomes.

Veröffentlichte Arbeiten charakterisieren receptor pharmacology, strukturelle Modifikationen und das pharmakokinetische Profil dieser Verbindungsklasse, zusammen mit protokolldefinierten Endpunkten, die in registrierten klinischen Programmen untersucht werden.

Die Chargenverifizierung von New-U und die externe Literatur sind getrennte Evidenzgrundlagen: Die Chargenprüfung belegt analytische Identität und Reinheit des geprüften Materials; veröffentlichte Studien beschreiben ihre eigenen Prüfmaterialien und Protokolle.

Molekulare Architektur

LY3298176 ist ein synthetisches Peptid aus 39 Aminosäuren, das in receptor-pharmacology-Studien als Agonist an zwei incretin receptors, GLP-1R und GIPR, statt nur an GLP-1R charakterisiert wurde.

Rezeptor-Pharmakologie

Die Literatur beschreibt das Profil als unausgewogen: volle GIPR potency kombiniert mit einem cAMP-biased GLP-1R signal. Vollständige Wegtabelle: Receptor Pharmacology unten.

Strukturelle Modifikationen

Veröffentlichte Strukturarbeiten beschreiben Aib2- und Aib13-Substitutionen, die auf protease resistance untersucht werden, sowie eine über einen γGlu/AEEA spacer an Lys20 gebundene C20 fatty diacid, untersucht als albumin-binding-Beitrag zu verlängerter systemischer Exposition.

Veröffentlichte Pharmakokinetik

Die scheinbare Eliminationshalbwertszeit wird mit etwa fünf Tagen bei ungefähr 80% subkutaner Bioverfügbarkeit angegeben. Vollständiges Profil: siehe Pharmacokinetics unten.

Klinische Forschung

Die auf dieser Seite zusammengefassten veröffentlichten Befunde beziehen sich auf externe klinische Studien des Referenzarzneimittels und deren jeweilige Materialien und Protokolle. Sie belegen weder Sicherheit, Wirksamkeit noch klinische Gleichwertigkeit des New-U-Materials GLP1-RC-TZ.

Primärreferenzen

Peer-reviewed publications und registrierte trial records sind vollständig mit DOI/PMID/NCT-Identifikatoren in Source References unten aufgeführt.

At a glance

Mechanism and receptors Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Clinical research SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme.

Molecular characteristics Molecular weight 4,813.53 Da.

Pharmacokinetics Half-life: Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks.

Evidence maturity Tier 1: Human clinical — The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials.

Analytical verification Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Research limitations Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Receptor Pharmacology

Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GIPR Full agonist activity characterised experimentally, comparable to native GIP The arm that distinguishes the dual agonist from single GLP-1R compounds in the literature GLP-1R Agonist activity characterised as biased, favouring cAMP signalling over β-arrestin recruitment Investigated in relation to receptor desensitisation over prolonged exposure Adipose GIPR signalling Direct GIPR-mediated adipose effects characterised experimentally Investigated as a contributor to measured insulin-sensitivity markers and adiponectin Albumin-binding modification C20 eicosanedioic acid via a γGlu/AEEA spacer; 99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~5-day apparent half-life) Proteolytic stability Aib2 and Aib13 substitutions Structural modifications investigated for altered peptide stability against DPP-IV and proteases

Deeper dive for scientific readers

The imbalanced-agonism profile is characterised in JCI Insight (2020): full GIPR potency layered onto a cAMP-biased GLP-1R signal. In SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024) investigators reported a mean change from baseline in body weight of −20.9% at week 72 in the 15 mg arm. SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) was designed as a head-to-head comparison against semaglutide and reported −20.2% vs −13.7% at week 72. SURPASS-CVOT (NEJM 2025) compared cardiovascular outcomes against dulaglutide and reported an approximately 8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality. Insulin-sensitivity improvements beyond what change in body weight alone accounts for are discussed in the literature as consistent with direct GIPR-mediated adipose effects. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

Was ist Tirzepatide in der wissenschaftlichen Forschung?

Tirzepatide (LY3298176) ist ein synthetisches Peptid aus 39 Aminosäuren, das in receptor-pharmacology studies als dualer GIP / GLP-1 receptor agonist mit imbalanced agonism charakterisiert wurde. Es ist in einigen Rechtsordnungen unter Markennamen anderer Hersteller als Arzneimittel zugelassen; das hier bereitgestellte Material ist nicht dieses finished pharmaceutical.

Was ist GLP1-RC-TZ?

GLP1-RC-TZ ist die New-U-Katalogbezeichnung für das im Rahmen dieses Forschungsprofils angebotene Material für laboratory research. Es ist kein Arzneimittel, keine Behandlung, kein generisches pharmazeutisches Produkt und kein therapeutisches Produkt, ist keinem klinischen oder kommerziellen Produkt gleichwertig und wird nicht für die Anwendung bei Menschen oder Tieren angeboten.

Welche Rezeptorsysteme werden in der Tirzepatide-Forschung untersucht?

Veröffentlichte in-vitro-Pharmakologie charakterisiert zwei Rezeptoren: GIPR, dessen Agonistenpotenz als nativem GIP vergleichbar berichtet wird, und GLP-1R, dessen Signalisierung Berichten zufolge cAMP-Generierung gegenüber β-arrestin recruitment bevorzugt. Strukturelle Arbeiten untersuchen zusätzlich die C20 fatty-diacid albumin-binding-Modifikation sowie Aib2/Aib13-Substitutionen für veränderte proteolytische Stabilität.

Welche analytischen Tests begleiten GLP1-RC-TZ?

The published GLP1-RC-TZ Certificate of Analysis comes from an independent analytical laboratory and records the independent laboratory, report number, measured purity and test date for the sample analysed; the method and any identity result are stated on the report itself. Vials are not batch-marked, so a certificate describes the sample tested rather than a particular vial or order. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current Certificate of Analysis for GLP1-RC-TZ?

The current certificate — laboratory, report number, measured purity and test date — is published at /coa/tirzepatide, together with the testing history for the compound.

Was bedeutet >99% HPLC purity?

Es handelt sich um einen Reinheitswert aus reversed-phase high-performance liquid chromatography mit area normalisation: Der Zielpeak macht mehr als 99% der gesamten integrierten Peakfläche im Chromatogramm der getesteten Probe aus. Dies ist ausschließlich eine Aussage über die chemische Reinheit dieser Probe und sagt nichts über Sterilität, Endotoxingehalt, pharmazeutische Gleichwertigkeit oder irgendeine klinische Eigenschaft aus.

Auf welche klinischen Studien wird auf dieser Seite Bezug genommen?

Drei externe Studien zum Referenzarzneimittel: SURMOUNT-1 (Jastreboff et al., NEJM 2022; PMID 35658024), SURMOUNT-5 (Aronne et al., NEJM 2025; PMID 40353578) und SURPASS-CVOT (NEJM 2025; DOI 10.1056/NEJMoa2505928), zusammen mit der receptor-pharmacology characterisation in JCI Insight (2020). Jedes auf dieser Seite berichtete Ergebnis wird der jeweiligen Studie, dem Arm und dem Zeitpunkt zugeordnet.

Wie wird veröffentlichte klinische Forschung von New-U Batch testing unterschieden?

They are separate bodies of evidence. Published clinical research is external work on the approved finished pharmaceutical, conducted under those studies' own protocols; it establishes nothing about the material supplied here. New-U certificate testing is analytical work on a submitted sample of the GLP1-RC-TZ material: the published report states the measured result for the sample analysed, and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-TZ.

Ist GLP1-RC-TZ dasselbe wie ein zugelassenes Markenmedikament?

Nein. Zugelassene Markenprodukte mit tirzepatide sind verschreibungspflichtige, sterile finished pharmaceuticals, die unter cGMP von ihrem marketing authorisation holder hergestellt werden. GLP1-RC-TZ ist nicht zugelassenes laboratory research material, das als lyophilisiertes Pulver bereitgestellt wird. Es ist weder gleichwertig noch ein Generikum oder Ersatz für irgendein zugelassenes Produkt.

Warum wird Tirzepatide in der Literatur als unausgewogen beschrieben?

Die beiden Rezeptorarme sind nicht gleichgewichtet: Die veröffentlichte Pharmakologie berichtet am GIPR eine volle Agonistenpotenz vergleichbar mit nativem GIP, am GLP-1R jedoch eine verzerrte Signalgebung, die cAMP-Bildung gegenüber β-arrestin-Rekrutierung bevorzugt. Die Literatur untersucht diese Asymmetrie im Zusammenhang mit Rezeptordesensibilisierung bei längerer Exposition.

Wie unterscheidet sich Tirzepatide-Forschung von Retatrutide- und Semaglutide-Forschung?

Nach der in der Literatur charakterisierten Rezeptorabdeckung beschreibt die semaglutide-Forschung GLP-1R-Agonismus, die tirzepatide-Forschung GIPR/GLP-1R-Agonismus und die retatrutide-Forschung GLP-1R/GIPR/GCGR-Agonismus. Nur SURMOUNT-5 wurde als direkter Vergleich konzipiert (tirzepatide vs semaglutide); Ergebnisse aus getrennten Programmen sind keine direkten Head-to-Head-Vergleiche.

In welcher Form wird GLP1-RC-TZ bereitgestellt?

GLP1-RC-TZ is supplied as a lyophilised powder in sealed vials, in sealed 10-vial research packs across the listed strengths; the Certificate of Analysis is published on the product page.

Wie sollte Material für laboratory research gelagert werden?

Das lyophilisierte Pulver in einem Gefrierschrank bei −20 °C lagern. Wenn ein Laborprotokoll das Material in Lösung erfordert, die resultierende Lösung bei 1–6 °C gekühlt und lichtgeschützt halten und wiederholte freeze–thaw cycles vermeiden, die die fatty-acid-Modifikation abbauen können. Lagerbedingungen sind ausschließlich Informationen zur Laborhandhabung.

Is it legal to buy Tirzepatide?

In the United States, Tirzepatide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 5 days (mean 116.7 h); steady-state exposure reported after ~4 weeks Absorption route Study protocols used subcutaneous administration; reported Tmax 8–72 h Bioavailability ~80% subcutaneous reported Metabolism / clearance Proteolytic backbone cleavage, β-oxidation of the C20 fatty-diacid chain and amide hydrolysis reported; metabolites eliminated ~66% renally / ~33% faecally; no CYP-mediated interactions Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~10.3 L; 99% albumin-bound. These are pharmacokinetic observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

SURMOUNT-1 RCT (Jastreboff et al., NEJM 2022; PMID 35658024), obesity/overweight population, 15 mg arm: investigators reported a mean change from baseline in body weight of −20.9% at week 72

SURMOUNT-5 head-to-head RCT (Aronne et al., NEJM 2025; PMID 40353578): investigators reported −20.2% in the tirzepatide arm vs −13.7% in the semaglutide arm at week 72

SURPASS-CVOT RCT (NEJM 2025), 13,000+ participants vs dulaglutide: investigators reported an ~8% relative reduction in major adverse cardiovascular events and a 16% relative reduction in all-cause mortality

SURPASS diabetes programme: investigators reported HbA1c reductions of up to 2.58% as a protocol-defined endpoint

Insulin-sensitivity markers and adiponectin recorded as measured endpoints, discussed in the literature in relation to direct GIPR-mediated adipose signalling

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The SURPASS and SURMOUNT programmes included 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg arms, with a protocol-defined step-up period of roughly 20 weeks before the maintenance arm level was reached. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Decreased appetite and dyspepsia recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Hypersensitivity and injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Tirzepatide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material.

Tier 1 · Human clinical

SURMOUNT-1 obesity RCT — −20.9% mean change from baseline in body weight at week 72 (NEJM 2022; PMID 35658024)

SURMOUNT-5 head-to-head RCT vs semaglutide — −20.2% vs −13.7% at week 72 (NEJM 2025; PMID 40353578)

SURPASS-CVOT cardiovascular-outcomes RCT — 13,000+ participants (NEJM 2025); SURPASS diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. · 2022 · PMID: 35658024 · DOI: 10.1056/NEJMoa2206038

Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. · 2025 · PMID: 40353578 · DOI: 10.1056/NEJMoa2416394

SURPASS-CVOT: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2505928

PubMed: peer-reviewed literature on Tirzepatide

ClinicalTrials.gov: registered studies on Tirzepatide

Tirzepatide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

39-amino-acid synthetic peptide built on the GIP backbone (LY3298176)

Dual GIPR / GLP-1R agonist activity characterised with imbalanced agonism

Aib2 and Aib13 substitutions investigated for DPP-IV and protease resistance

C20 fatty-diacid modification reported to give 99% albumin binding

Apparent elimination half-life reported at approximately 5 days in published pharmacokinetic research

GLP1-RC-TZ laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

New-U-Katalogidentifikator GLP1-RC-TZ Wissenschaftliches Thema Tirzepatide (LY3298176) Molekulargewicht 4,813.53 Da Rezeptoren charakterisiert GIPR (vollständiger Agonist), GLP-1R (cAMP-biased) Reinheit (analytisch) >99% mittels RP-HPLC-Flächennormalisierung Identität (analytisch) Stated on the published Certificate of Analysis where the report includes an identity test Form Lyophilisiertes Pulver Veröffentlichte Halbwertszeit Etwa 5 Tage, Mittelwert 116.7 h (externe pharmakokinetische Forschung) Lagerung Lyophilisiert: −20 °C Gefrierschrank. Rekonstituiert: 1–6 °C, vor Licht geschützt. Vorgesehene Verwendung Laboratory research material. Not for human or veterinary use.

Tirzepatide Research — GLP1-RC-TZ Laboratory Research Material

Tirzepatide is the most extensively characterised dual-incretin ("twincretin") peptide in the published literature. Receptor-pharmacology studies describe full GIPR agonist potency layered onto a cAMP-biased GLP-1R signal, and the clinical programme includes one trial, SURMOUNT-5 (NEJM 2025), specifically designed as a head-to-head comparison against semaglutide.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −20.9% at week 72 in the SURMOUNT-1 15 mg arm (NEJM 2022), −20.2% vs −13.7% against semaglutide at week 72 in SURMOUNT-5 (NEJM 2025), an ~8% relative reduction in major adverse cardiovascular events against dulaglutide in SURPASS-CVOT (NEJM 2025), and HbA1c reductions of up to 2.58% in the SURPASS programme. Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-TZ as lyophilised, analytically verified laboratory research material ; its published independent Certificate of Analysis records the independent laboratory, report number, measured purity and test date for the sample analysed. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-TZ research material. GLP1-RC-TZ is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

Gastric inhibitory polypeptide - Wikipedia

Customer Reviews

Everything arrived safely

Order reached me in good condition and the contents matched the basket. All good here.

- Channan R***** · 20 October 2026

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Semaglutide Semaglutide is a long-acting GLP-1 receptor agonist characterised in published research, with 94% homology to native human GLP-1 and a C18 fatty-diacid albumin-binding modification. GLP1-RC-SM is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Semaglutide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Metabolic Research Liraglutide Liraglutide is a GLP-1 receptor agonist: a 31-residue analogue of GLP-1(7-37) with an Arg34 substitution and a C16 palmitoyl-γ-glutamate side chain on Lys26 that promotes albumin binding. Liraglutide →

Tirzepatide vs related Metabolic Research compounds

Compound Price Purity spec COA Tirzepatide from $168 >99% HPLC 2 published batches Retatrutide from $160 >99% HPLC 4 published batches Semaglutide from $106 >99% HPLC 1 published batch

Tirzepatide vs Retatrutide - full comparison

Tirzepatide vs Semaglutide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Tirzepatide

Metabolic Research research compounds

Tirzepatide research guide

Tirzepatide pricing and packs

Research this compound

Research guide Tirzepatide research guide Published experimental work characterises dual GIPR / GLP-1R agonist activity with imbalanced agonism, plus an albumin-binding structural… Read the guide →

Compare Compare Tirzepatide and Liraglutide Tirzepatide vs Liraglutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Tirzepatide COA Latest published certificate of analysis (purity and identity), dated 2026-05-27. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research